July 21, 2023 — AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced a partnership with the Jefferson Narcotic Addiction Rehabilitation Program (NARP) and Thomas Jefferson University Hospital in Philadelphia to evaluate the benefits of QTc monitoring with KardiaMobile 6L for patients receiving methadone maintenance therapy for opioid use disorder.
In the six-month pilot study, healthcare professionals will use KardiaMobile 6L, the only medical-grade, six-lead personal ECG device that is FDA-cleared to measure QTc intervals, to detect QT prolongation, a potentially dangerous side effect associated with certain medications like methadone.
“We are excited to partner with Thomas Jefferson University Hospital on this important study that will illuminate the benefits of real-time QTc interval monitoring with KardiaMobile 6L on patients’ outcomes and their treatment experience,” said Patricia Baran, Senior Vice President, Enterprise North America & Biopharma Worldwide. “By enabling clinicians to efficiently detect cardiac side effects, they can better counsel patients about taking the appropriate steps to mitigate risks to their heart health.”
“Rapid, point-of-care devices can have an important role in streamlining the cardiac safety monitoring required by many behavioral disorder medicines, which are a critical part of comprehensive treatment strategies for people with substance use disorders,” said William Jangro, DO, Medical Director, Jefferson NARP.
“We look forward to assessing how efficient QTc monitoring with KardiaMobile 6L increases compliance with guideline recommendations, improves the patient experience, enhances treatment, and allows for interdepartmental collaboration,” said Daniel Frisch, MD, Associate Professor of Medicine Electrophysiology Section, Thomas Jefferson University Hospital.
KardiaMobile 6L was cleared by the FDA in July 2021 for use by healthcare professionals to calculate patients’ QTc interval.
About the Pilot Study:
During the six-month pilot, each new patient and each patient undergoing an annual physical at Jefferson NARP will have their ECG recorded with KardiaMobile 6L to detect potential QT prolongation. Recordings will be automatically uploaded to the clinic’s KardiaStation, AliveCor’s workflow solution for in-person instant ECG analysis.
For more information: www.alivecor.com
Related ECG Content:
Find News on New ECG Technology
Trends in ECG Management Systems
VIDEO: Screening for Atrial Fibrillation Using Single Lead ECG in the VITAL-AF Trial — Presented at AHA 2020
ECG Industry Blooms With Innovative Devices and New Methods
Advances in ECG Management Systems
A Double-Edged Sword: How Over-the-Counter ECG Devices are Impacting Cardiac Care
Artificial Intelligence Examining ECGs Predicts Irregular Heartbeat, Death Risk
AI Could Use EKG Data to Measure Patient's Overall Health Status
Smartphones Used to Successfully Screen More than 60,000 for Atrial Fibrillation
FDA Clears AliveCor's KardiaMobile 6L as First Six-Lead Personal ECG Device
VIDEO: ECG System Uses 3-D Interactive Image to Show Proper Lead Placements
EKG With Artificial Intelligence Reliably Detects Heart Failure Precursor
Algorithms to Automate Review of Mobile ECG Device Data, Detection of Arrhythmias
FDA Clears First AI-Powered Algorithm Suite for Personal ECG Monitoring
May 08, 2026 
